Dorothee Thuillier
Overview
Explore the profile of Dorothee Thuillier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1865
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Delfin C, Dragan I, Kuznetsov D, Tajes J, Smit F, Coral D, et al.
Life (Basel)
. 2024 Feb;
14(2).
PMID: 38398771
Obesity is considered by many as a lifestyle choice rather than a chronic progressive disease. The Innovative Medicines Initiative (IMI) SOPHIA (Stratification of Obesity Phenotypes to Optimize Future Obesity Therapy)...
2.
Mancina R, Sasidharan K, Lindblom A, Wei Y, Ciociola E, Jamialahmadi O, et al.
Nat Metab
. 2022 Feb;
4(1):60-75.
PMID: 35102341
Fatty liver disease (FLD) is a growing health issue with burdening unmet clinical needs. FLD has a genetic component but, despite the common variants already identified, there is still a...
3.
Paccou J, Thuillier D, Courtalin M, Pigny P, Labreuche J, Cortet B, et al.
Surg Obes Relat Dis
. 2022 Jan;
18(3):373-383.
PMID: 34973928
Background: It is still debated whether differences in bone turnover markers (BTMs) exist between the 2 most popular bariatric surgery procedures (Roux-en-Y gastric bypass [RYGB] and sleeve gastrectomy [SG]). Objectives:...
4.
Grzych G, Chavez-Talavera O, Descat A, Thuillier D, Verrijken A, Kouach M, et al.
JHEP Rep
. 2021 Feb;
3(2):100222.
PMID: 33615207
Background & Aims: Plasma bile acids (BAs) have been extensively studied as pathophysiological actors in non-alcoholic steatohepatitis (NASH). However, results from clinical studies are often complicated by the association of...
5.
Jamialahmadi O, Mancina R, Ciociola E, Tavaglione F, Luukkonen P, Baselli G, et al.
Gastroenterology
. 2020 Dec;
160(5):1634-1646.e7.
PMID: 33347879
Background & Aims: Fatty liver disease (FLD) is a growing epidemic that is expected to be the leading cause of end-stage liver disease within the next decade. Both environmental and...
6.
Vandel J, Dubois-Chevalier J, Gheeraert C, Derudas B, Raverdy V, Thuillier D, et al.
Hepatology
. 2020 May;
73(3):920-936.
PMID: 32394476
Background And Aims: Nonalcoholic steatohepatitis (NASH) is considered as a pivotal stage in nonalcoholic fatty liver disease (NAFLD) progression, given that it paves the way for severe liver injuries such...
7.
Schmidt A, Holmes M, Preiss D, Swerdlow D, Denaxas S, Fatemifar G, et al.
BMC Cardiovasc Disord
. 2019 Oct;
19(1):240.
PMID: 31664920
Background: We characterised the phenotypic consequence of genetic variation at the PCSK9 locus and compared findings with recent trials of pharmacological inhibitors of PCSK9. Methods: Published and individual participant level...
8.
Margerie D, Lefebvre P, Raverdy V, Schwahn U, Ruetten H, Larsen P, et al.
BMC Med Genomics
. 2019 Jun;
12(1):80.
PMID: 31159817
Background: Clinical data identified an association between the use of HMG-CoA reductase inhibitors (statins) and incident diabetes in patients with underlying diabetes risk factors such as obesity, hypertension and dyslipidemia....
9.
Montagne L, Derhourhi M, Piton A, Toussaint B, Durand E, Vaillant E, et al.
Mol Metab
. 2018 May;
13:1-9.
PMID: 29784605
Objective: The molecular diagnosis of extreme forms of obesity, in which accurate detection of both copy number variations (CNVs) and point mutations, is crucial for an optimal care of the...
10.
Flannick J, Fuchsberger C, Mahajan A, Teslovich T, Agarwala V, Gaulton K, et al.
Sci Data
. 2018 Jan;
5:180002.
PMID: 29360107
This corrects the article DOI: 10.1038/sdata.2017.179.